Spago Nanomedical AB announced that the independent data monitoring committee has recommended a dose escalation in the company’s clinical phase I/IIa study Tumorad-01 with the candidate drug 177Lu-SN201.
Spago Nanomedical AB announced that the independent data monitoring committee has recommended a dose escalation in the company’s clinical phase I/IIa study Tumorad-01 with the candidate drug 177Lu-SN201.